Sipuleucel-T is the first FDA-approved therapeutic cancer vaccine. It
is approved for the treatment of asymptomatic or minimally symptomatic
metastatic castration-resistant (hormone-refractory) prostate cancer.
Sipuleucel-T is described as a therapy rather than a precisely defined
therapeutic agent because it is an autologous vaccine that is generated
from each individual patient's own blood cells.
